CERUS CORP (CERS) — SEC Financial Statements & Analysis

CERUS CORP (CERS) is a surgical & medical instruments & apparatus company, incorporated in DE. CERUS CORP trades on Nasdaq as: CERS. CERUS CORP (CERS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, CERUS CORP carries a market cap of $585.65M, a P/E ratio of -85.80x, a P/B ratio of 8.28x, a P/S ratio of 2.35x, an enterprise value of $631.96M, and an EV/EBITDA multiple of 9575.13x. On profitability, it posts a gross margin of 46.27%, an operating margin of -0.65%, a net margin of -2.74%, a Return on Equity (ROE) of -10.76%, a Return on Assets (ROA) of -3.26%, and a Return on Invested Capital (ROIC) of -1.29%. Per share, it reports EPS of $-0.03, diluted EPS of $-0.03, free cash flow per share of $-0.01, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 16.70% year-over-year, net income growth of -63.94% year-over-year, and EPS growth of -65.60% year-over-year. On the balance sheet, it maintains a current ratio of 1.83x, a quick ratio of 1.02x, working capital of $71.52M, a debt-to-equity ratio of 1.90x, a debt ratio of 0.66, an interest coverage ratio of -0.21x, free cash flow of $-1.83M (TTM), and net debt of $46.31M. Figures sourced from SEC EDGAR.

Market Cap

$585.65M

P/E TTM

-85.80x

EPS TTM

$-0.03

P/B TTM

8.28x

ROE TTM

-10.76%

ROA TTM

-3.26%

Debt To Equity

1.90x

Free Cash Flow TTM

$-1.83M

Net Revenue TTM Growth 1Y

16.70%

Data as of 2026-06-30 · Source: SEC EDGAR